Collegium Pharmaceutical (NASDAQ:COLL) Given “Buy” Rating at HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $50.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 49.97% from the stock’s previous close.

A number of other research firms also recently commented on COLL. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL opened at $33.34 on Friday. The firm’s 50-day moving average price is $30.57 and its 200-day moving average price is $34.04. Collegium Pharmaceutical has a 52-week low of $28.39 and a 52-week high of $42.29. The company has a market cap of $1.08 billion, a PE ratio of 14.37 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of COLL. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after purchasing an additional 821,541 shares during the period. Rubric Capital Management LP lifted its position in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after buying an additional 499,473 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after acquiring an additional 215,874 shares during the period. Emerald Advisers LLC increased its holdings in Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after acquiring an additional 177,129 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.